CCS
XBI icon

Crosspoint Capital Strategies’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Crosspoint Capital Strategies’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-48
Closed -$4K – 896
2015
Q2 		$4K Buy
+48
New +$3.73K ﹤0.01% 586

Other funds holding XBI

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Crosspoint Capital Strategies's XBI Position: Q3 2015 in Review

Crosspoint Capital Strategies sold out of State Street SPDR S&P Biotech ETF (XBI) in Q3 2015, closing a stake of 48 shares — an estimated $4K sold.

Crosspoint Capital Strategies first reported a position in XBI in Q2 2015 and held it in 1 quarter. The position peaked at $4K in Q2 2015. 196 funds tracked by Wall St. Rank hold XBI as of Q3 2015.

  • Crosspoint Capital Strategies reported no remaining State Street SPDR S&P Biotech ETF position as of Q3 2015 after selling out during the quarter.
  • Crosspoint Capital Strategies sold 48 State Street SPDR S&P Biotech ETF shares in Q3 2015, an estimated $4K.
  • Crosspoint Capital Strategies first reported a position in State Street SPDR S&P Biotech ETF in Q2 2015 and held it in 1 quarter.
  • Crosspoint Capital Strategies's State Street SPDR S&P Biotech ETF position peaked at $4K in Q2 2015.
  • 196 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2015.

Based on Crosspoint Capital Strategies's 13F filing for Q3 2015, filed 25 Nov 2015.